Medivir AB announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.
| STOCKHOLM, April 9, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024. CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox’s development program. Investing in Oncology Forum – hosted by Cord Communications and focusing on what difference Swedish commercial drug development can make in creating the cancer therapies of tomorrow. The presentation will be available on Medivir’s website www.medivir.com after the meeting. For additional information, please contact Magnus Christensen, CFO, Medivir AB Medivir in brief Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Medivir | ||||
Company Codes: Bloomberg:MVIR@SS, ISIN:SE0020181014, RICS:MVIR.ST, Stockholm:MVIR |
View original content:
